{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:57:20Z","timestamp":1792803440312,"version":"4.5.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s10637-020-00974-7","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T10:03:41Z","timestamp":1594375421000},"page":"251-255","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Anti-transcriptional intermediary factor 1-\u03b3 antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3230-3431","authenticated-orcid":false,"given":"Megumu","family":"Osaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Tachikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichiro","family":"Ohira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Tomii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,10]]},"reference":[{"key":"974_CR1","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41584-018-0074-9","volume":"14","author":"LH Calabrese","year":"2018","unstructured":"Calabrese LH, Calabrese C, Cappelli LC (2018) Rheumatic immune-related adverse events from cancer immunotherapy. Nat Rev Rheumatol 14:569\u2013579","journal-title":"Nat Rev Rheumatol"},{"key":"974_CR2","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1684\/ejd.2016.2770","volume":"26","author":"Y Yamaguchi","year":"2016","unstructured":"Yamaguchi Y, Abe R, Haga N, Shimizu H (2016) A case of drug-associated dermatomyositis following ipilimumab therapy. Eur J Dermatol 26:320\u2013321","journal-title":"Eur J Dermatol"},{"key":"974_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ejca.2018.08.021","volume":"104","author":"M Berger","year":"2018","unstructured":"Berger M, Legeay AL, Souci S, Streichenberger N, Thomas L, Dalle S (2018) Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma. Eur J Cancer 104:227\u2013230","journal-title":"Eur J Cancer"},{"key":"974_CR4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158\u2013168","journal-title":"N Engl J Med"},{"key":"974_CR5","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.2169\/internalmedicine.9518-17","volume":"57","author":"M Shiba","year":"2018","unstructured":"Shiba M, Inaba H, Ariyasu H, Kawai S, Inagaki Y, Matsuno S, Iwakura H, Yamamoto Y, Nishi M, Akamizu T (2018) Fulminant type 1 diabetes mellitus accompanied by positive conversion of anti-insulin antibody after the administration of anti-CTLA-4 antibody following the discontinuation of anti-PD-1 antibody. Intern Med 57:2029\u20132034","journal-title":"Intern Med"},{"key":"974_CR6","doi-asserted-by":"publisher","first-page":"838","DOI":"10.4065\/mcp.2010.0099","volume":"85","author":"LC Pelosof","year":"2010","unstructured":"Pelosof LC, Gerber DE (2010) Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc 85:838\u2013854","journal-title":"Mayo Clin Proc"},{"key":"974_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s13317-014-0060-4","volume":"5","author":"A Ghirardello","year":"2014","unstructured":"Ghirardello A, Borella E, Beggio M, Franceschini F, Fredi M, Doria A (2014) Myositis autoantibodies and clinical phenotypes. Auto Immun Highlights 5:69\u201375","journal-title":"Auto Immun Highlights"},{"key":"974_CR8","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41571-019-0194-4","volume":"16","author":"F Graus","year":"2019","unstructured":"Graus F, Dalmau J (2019) Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol 16:535\u2013548","journal-title":"Nat Rev Clin Oncol"},{"key":"974_CR9","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1001\/jamaoncol.2016.2238","volume":"2","author":"SA Khan","year":"2016","unstructured":"Khan SA, Pruitt SL, Xuan L, Gerber DE (2016) Prevalence of autoimmune disease among patients with lung cancer: implications for immunotherapy treatment options. JAMA Oncol 2:1507\u20131508","journal-title":"JAMA Oncol"},{"key":"974_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","volume":"44","author":"L Spain","year":"2016","unstructured":"Spain L, Diem S, Larkin J (2016) Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44:51\u201360","journal-title":"Cancer Treat Rev"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00974-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-020-00974-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00974-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:53:07Z","timestamp":1678510387000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-020-00974-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,10]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["974"],"URL":"https:\/\/doi.org\/10.1007\/s10637-020-00974-7","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,10]]},"assertion":[{"value":"15 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}